CASE REPORT article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1626721

This article is part of the Research TopicModulating B Cell Subsets: Future Therapeutics for Autoimmune DiseasesView all articles

A patient presenting primarily with psychosis of NPSLE treated with telitacicept, corticosteroids, and immunosuppressants: A case report

Provisionally accepted
Wei  XieWei XiePeijue  ChenPeijue ChenLili  LuoLili Luo*
  • Mianyang Third People's Hospital, Mianyang, China

The final, formatted version of the article will be published soon.

Therapeutic strategies for neuropsychiatric systemic lupus erythematosus (NPSLE) primarily target underlying pathogenic mechanisms and typically include corticosteroids, immunosuppressants, anticoagulation, and adjunctive treatments. B-cell-targeted biologics are an emerging option for NPSLE. Although telitacicept is approved for systemic lupus erythematosus (SLE) treatment in China, evidence supporting its use in NPSLE remains limited. This case report presents a 20-year-old female diagnosed with NPSLE who exhibited psychotic symptoms as the predominant manifestation and was treated with telitacicept, corticosteroids, and immunosuppressants. During the treatment period, her psychiatric symptoms remained in remission without infections or adverse events. Her disease activity score (SLEDAI-2000) declined from 23 to 2.

Keywords: neuropsychiatric systemic lupus erythematosus, Telitacicept, biologics, Treatment, case report

Received: 11 May 2025; Accepted: 26 Jun 2025.

Copyright: © 2025 Xie, Chen and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lili Luo, Mianyang Third People's Hospital, Mianyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.